ABL1 and leukemia: FDA-approved drugs targeting ABL1/2 have been utilized for decades to treat leukemias driven by activated forms of ABL1 (e.g., BCR-ABL) [8]); therefore, repurposing these agents for treatment-refractory melanomas would be an attractive treatment strategy.